Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Oct;70(1):94–101.

Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin.

J L Fan 1, K Himeno 1, S Tsuru 1, K Nomoto 1
PMCID: PMC1542222  PMID: 3500817

Abstract

The autoimmune manifestations of MRL/Mp-lpr/lpr(MRL/l), a murine model of systemic lupus erythematosus (SLE), were alleviated by administering 1 microgram cholera toxin (CT) every 14 days. The beneficial effects were: (i) significant prolongation of survival time, (ii) prevention of lymphadenopathy, (iii) improvement of T cell mitogenic responses and suppression of a B cell mitogenic response, (iv) decrease in serum anti-DNA and anti-Sm antibodies, (v) increase in IL-2 production by stimulation of spleen cells with concanavalin A (Con A). It is possible that CT may be effective for treatment of murine lupus nephritis by modulating polyclonal lymphocyte activation. This type of immunomodulation may pave the way toward treatment of lupus and other autoimmune diseases.

Full text

PDF
94

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews B. S., Eisenberg R. A., Theofilopoulos A. N., Izui S., Wilson C. B., McConahey P. J., Murphy E. D., Roths J. B., Dixon F. J. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med. 1978 Nov 1;148(5):1198–1215. doi: 10.1084/jem.148.5.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berden J. H., Hang L., McConahey P. J., Dixon F. J. Analysis of vascular lesions in murine SLE. I. Association with serologic abnormalities. J Immunol. 1983 Apr;130(4):1699–1705. [PubMed] [Google Scholar]
  3. Brennan F. M., Williams D. G., Bovill D., Stocks M. R., Maini R. N. Administration of monoclonal anti-Sm antibody prolongs the survival and renal function of MRL-lpr/lpr mice. Clin Exp Immunol. 1986 Jul;65(1):42–50. [PMC free article] [PubMed] [Google Scholar]
  4. Cameron R., Waterfield J. D. Delineation of two defects responsible for T-cell hyporesponsiveness to concanavalin A in MRL congenic mice. Immunology. 1986 Oct;59(2):187–193. [PMC free article] [PubMed] [Google Scholar]
  5. Dang H., Fischbach M., Lerner E., Talal N. Molecular and antigenic nature of isolated Sm. J Immunol. 1983 Jun;130(6):2782–2785. [PubMed] [Google Scholar]
  6. Dueymes M., Fournie G. J., Carentz F., Mignon-Conte M., Labarre J. F., Conte J. J. In vivo modulation of polyclonal activation of lymphocytes by SOAz, a cyclophosphazene derived drug. Prevention of murine glomerulonephritis induced by chronic injections of lipopolysaccharide. Clin Exp Immunol. 1985 Jan;59(1):169–176. [PMC free article] [PubMed] [Google Scholar]
  7. Dueymes M., Fournié G. J., Mignon-Conté M., In S., Conté J. J. Prevention of lupus diseases in MRL/1, NZBxNZW, and BXSB mice treated with a cyclophosphazene derived drug. Clin Immunol Immunopathol. 1986 Nov;41(2):193–205. doi: 10.1016/0090-1229(86)90103-0. [DOI] [PubMed] [Google Scholar]
  8. Eisenberg R. A., Tan E. M., Dixon F. J. Presence of anti-Sm reactivity in autoimmune mouse strains. J Exp Med. 1978 Feb 1;147(2):582–587. doi: 10.1084/jem.147.2.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hart D. A., Finkelstein R. A. Inhibition of mitogen stimulation of human peripheral blood leukocytes by Vibrio cholerae enterotoxin. J Immunol. 1975 Jan;114(1 Pt 2):476–480. [PubMed] [Google Scholar]
  10. Henney C. S., Lichtenstein L. M., Gillespie E., Rolley R. T. In vivo suppression of the immune response to alloantigen by cholera enterotoxin. J Clin Invest. 1973 Nov;52(11):2853–2857. doi: 10.1172/JCI107481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kelley V. E., Winkelstein A., Izui S., Dixon F. J. Prostaglandin E1 inhibits T-cell proliferation and renal disease in MRL/1 mice. Clin Immunol Immunopathol. 1981 Nov;21(2):190–203. doi: 10.1016/0090-1229(81)90208-7. [DOI] [PubMed] [Google Scholar]
  12. Klinman D. M., Lefkowitz M. D., Raveche E. S., Steinberg A. D. Effect of anti-Ia treatment on the production of anti-DNA antibody by NZB mice. Eur J Immunol. 1986 Aug;16(8):939–944. doi: 10.1002/eji.1830160811. [DOI] [PubMed] [Google Scholar]
  13. Koizumi T., Nakao Y., Matsui T., Katakami Y., Nakagawa T., Fujita T. Synergistic induction by calcium ionophore and phorbol ester of interleukin-2 (IL-2) receptor expression, IL-2 production, and proliferation in autoimmune MRL/MP-lpr mice. Immunology. 1986 Sep;59(1):43–49. [PMC free article] [PubMed] [Google Scholar]
  14. Kotzin B. L., Arndt R., Okada S., Ward R., Thach A. B., Strober S. Treatment of NZB/NZW mice with total lymphoid irradiation: long-lasting suppression of disease without generalized immune suppression. J Immunol. 1986 May 1;136(9):3259–3265. [PubMed] [Google Scholar]
  15. Lichtenstein L. M., Henney C. S., Bourne H. R., Greenough W. B., 3rd Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest. 1973 Mar;52(3):691–697. doi: 10.1172/JCI107230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Morse S. I., Stearns C. D., Goldsmith S. R. Lymphocyte depletion induced by cholera toxin; relationship to adrenal cortical function. J Immunol. 1975 Feb;114(2 Pt 1):665–670. [PubMed] [Google Scholar]
  17. Sakaguchi S., Fukuma K., Kuribayashi K., Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med. 1985 Jan 1;161(1):72–87. doi: 10.1084/jem.161.1.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Seaman W. E., Wofsy D., Greenspan J. S., Ledbetter J. A. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J Immunol. 1983 Apr;130(4):1713–1718. [PubMed] [Google Scholar]
  19. Strom T. B., Carpenter C. B., Garovoy M. R., Austen K. F., Merrill J. P., Kaliner M. The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity. J Exp Med. 1973 Aug 1;138(2):381–393. doi: 10.1084/jem.138.2.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tan E. M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol. 1982;33:167–240. doi: 10.1016/s0065-2776(08)60836-6. [DOI] [PubMed] [Google Scholar]
  21. Theofilopoulos A. N., Dixon F. J. Etiopathogenesis of murine SLE. Immunol Rev. 1981;55:179–216. doi: 10.1111/j.1600-065x.1981.tb00343.x. [DOI] [PubMed] [Google Scholar]
  22. Theofilopoulos A. N., Dixon F. J. Murine models of systemic lupus erythematosus. Adv Immunol. 1985;37:269–390. doi: 10.1016/s0065-2776(08)60342-9. [DOI] [PubMed] [Google Scholar]
  23. Tsuru S., Nomoto K., Oka M., Kitani H., Zinnaka Y., Takeya K. Augmented delayed footpad reaction in thymus cell-depleted mice induced by cholera toxoid. J Clin Lab Immunol. 1983 May;11(1):37–42. [PubMed] [Google Scholar]
  24. Tsuru S., Nomoto K., Oka M., Zinnaka Y. Effects of cholera toxin on the lymphoid system. III. In vivo generation of cytotoxic lymphocytes. J Clin Lab Immunol. 1983 Apr;10(4):209–214. [PubMed] [Google Scholar]
  25. Tsuru S., Nomoto K., Zinnaka Y., Takeya K. Effects of cholera toxin on lymphoid system. I. Reduction of thymus cells after cholera toxin injection. J Clin Lab Immunol. 1981 Sep;6(2):181–183. [PubMed] [Google Scholar]
  26. Tsuru S., Zinnaka Y., Nomoto K., Takeya K. Effects of cholera toxin on the lymphoid system II. Selective augmentation of delayed footpad reaction in mice. J Clin Lab Immunol. 1981 Sep;6(2):185–192. [PubMed] [Google Scholar]
  27. Warren K. S., Mahmoud A. A., Boros D. L., Rall T. W., Mandel M. A., Carpenter C. C., Jr In vivo suppression by cholera toxin of cell-mediated and foreign body inflammatory responses. J Immunol. 1974 Mar;112(3):996–1007. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES